Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Consensus Target Price from Analysts

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) have received a consensus recommendation of "Hold" from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

A number of brokerages recently commented on VIGL. HC Wainwright cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $14.00 to $8.00 in a research report on Tuesday. Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a research report on Thursday, May 22nd. Citigroup cut shares of Vigil Neuroscience to a "market perform" rating in a research note on Thursday, May 22nd. Guggenheim set a $8.00 price objective on shares of Vigil Neuroscience and gave the stock a "neutral" rating in a research note on Thursday, May 22nd. Finally, William Blair cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd.

Institutional Trading of Vigil Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC lifted its holdings in Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after buying an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Vigil Neuroscience in the 4th quarter valued at approximately $83,000. Barclays PLC raised its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after purchasing an additional 49,000 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Trading Up 0.1%

Shares of NASDAQ:VIGL traded up $0.01 during midday trading on Friday, reaching $7.89. The company had a trading volume of 534,998 shares, compared to its average volume of 642,378. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95. The company's 50 day moving average price is $2.43 and its 200 day moving average price is $2.35. The stock has a market cap of $368.01 million, a P/E ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. Research analysts forecast that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.